NEW YORK, NY / ACCESSWIRE / January 14, 2016 / Park Lane Advisor has initiated coverage on the following equities: Neogenomics Inc. (NASDAQ: NEO), OraSure Technologies Inc. (NASDAQ: OSUR), Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH), and LeMaitre Vascular Inc. (NASDAQ: LMAT). Free research report on Neogenomics can be accessed at http://www.parklaneadvisor.com/ On Wednesday, January 13, 2016, the NASDAQ Composite ended at 4,526.06, down 3.41%, the Dow Jones Industrial Average declined 2.21%, to finish the day at 16,151.41, and the S&P 500 closed at 1,890.28, down 2.50%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
Neogenomics Inc.'s stock edged 0.45% higher, to close the day at $6.75. The stock recorded a trading volume of 0.31 million shares, below its three months average volume of 0.45 million shares. Neogenomics Inc.'s shares have surged 19.68% in the past three months and 60.71% in the past one year. However, the stock has lost 7.41% in the last one month. The company's shares are trading 8.14% above their 200-day moving average. Additionally, Neogenomics Inc. has a Relative Strength Index (RSI) of 30.29. Sign up and read the free notes on NEO at:
http://www.parklaneadvisor.com/
On Wednesday, shares in OraSure Technologies Inc. recorded a trading volume of 0.37 million shares, lower than their three months average volume of 0.52 million shares. The stock ended the day 4.90% lower at $5.63. Shares of the company traded at a PE ratio of 281.50. Although, OraSure Technologies Inc.'s stock has gained 25.39% in the past three months, it has declined 9.05% in the last one month and 45.71% in the last one year. The company is trading below its 50-day and 200-day moving averages by 8.73% and 1.63%, respectively. Furthermore, shares of OraSure Technologies Inc. have an RSI of 33.37. The complimentary notes on OSUR can be downloaded in PDF format at:
http://www.parklaneadvisor.com/
Tetraphase Pharmaceuticals Inc.'s stock finished Wednesday's session 9.20% lower at $5.53. A total of 0.92 million shares were traded, which was below its three months average volume of 0.98 million shares. Over the last one month and the previous three months, Tetraphase Pharmaceuticals Inc.'s shares have declined 43.57% and 32.40%, respectively. Additionally, the stock has plummeted 85.99% in the past one year. The company's shares are trading below their 50-day and 200-day moving averages by 45.58% and 80.57%, respectively. Tetraphase Pharmaceuticals Inc.'s stock has an RSI of 17.10. Register for free on Park Lane Advisor and access the latest research on TTPH at:
http://www.parklaneadvisor.com/
On Wednesday, shares in LeMaitre Vascular Inc. ended the session 1.73% higher at $15.89. The stock reported a trading volume of 0.23 million shares, above its three months average volume of 0.15 million shares. Shares of the company traded at a PE ratio of 39.73. LeMaitre Vascular Inc.'s shares have gained 1.60% in the last one month, 30.14% in the previous three months and 110.74% in the last one year. The company is trading 3.37% above its 50-day moving average and 27.43% above its 200-day moving average. Moreover, shares of LeMaitre Vascular Inc. have an RSI of 50.40. The complete research on LMAT is available for free at:
http://www.parklaneadvisor.com/
About Park Lane Advisor:
Park Lane Advisor ("PLA") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. PLA has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PLA has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
NO WARRANTY
PLA, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PLA nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit www.ParkLaneAdvisor.com
RESTRICTIONS
PLA is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
E-mail: media (at) ParkLaneAdvisor (dot) com
SOURCE: Park Lane Advisor
